FAP and colorectal carcinoma: In this context, the use of the humanized anti-FAP monoclonal antibody sibrotuzumab has been proposed in non-small cell lung and colorectal cancer (CRC), but the pilot study in CRC did not reach the minimal requirements for the continuation of the trial (163–166).